Last July, the agency placed a hold on the trial due to a chromatographic signal detected in a human ADME study of the ...

Tv Therapeutics (NASDAQ:VTVT) said on Monday that the U.S. FDA has lifted the clinical hold on cadisegliatin's clinical trial ...

The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.

Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...

Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...

Cadisegliatin, which was paused in the third phase of its CATT1 trial, is taken orally and is designed to target the liver specifically and aims to treat diabetes by improving blood sugar control. VTv ...

Tv Therapeutics (VTVT) announced that the United States Food and Drug Administration has lifted the clinical hold on the cadisegliatin ...

EDT vTv Therapeutics (VTVT) trading resumesLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities. Discover ...

The S&P 500 and growth-focused ETFs, like IVW, are experiencing sharp declines. Read why I maintain my buy rating on Vanguard ...

Below is Validea's ETF fundamental report for Vanguard Value ETF (VTV). The report looks at VTV's exposure to the major investing factors including value, quality, momentum and low volatility.

Below is Validea's ETF fundamental report for Vanguard Value ETF (VTV). The report looks at VTV's exposure to the major investing factors including value, quality, momentum and low volatility.

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati ...